Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Aclaris Therapeutics (ACRS) Return on Sales (2017 - 2025)

Aclaris Therapeutics (ACRS) has 9 years of Return on Sales data on record, last reported at 16.29% in Q4 2025.

  • For Q4 2025, Return on Sales fell 570.0% year-over-year to 16.29%; the TTM value through Dec 2025 reached 8.78%, down 163.0%, while the annual FY2025 figure was 8.78%, 173.0% down from the prior year.
  • Return on Sales reached 16.29% in Q4 2025 per ACRS's latest filing, down from 4.65% in the prior quarter.
  • Across five years, Return on Sales topped out at 0.23% in Q4 2023 and bottomed at 17.02% in Q2 2023.
  • Average Return on Sales over 5 years is 9.1%, with a median of 10.23% recorded in 2021.
  • Peak YoY movement for Return on Sales: crashed -1587bps in 2021, then surged 1305bps in 2024.
  • A 5-year view of Return on Sales shows it stood at 15.25% in 2021, then soared by 75bps to 3.75% in 2022, then surged by 94bps to 0.23% in 2023, then crashed by -4499bps to 10.59% in 2024, then crashed by -54bps to 16.29% in 2025.
  • Per Business Quant database, its latest 3 readings for Return on Sales were 16.29% in Q4 2025, 4.65% in Q3 2025, and 9.22% in Q2 2025.